You are here

  • Home
  • Archive
  • Volume 83, Issue 2
  • Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

Responses

Article menu
Spondyloarthritis
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 11 January 2024
    Bimekizumab's Remarkable Potential in Transforming Axial Spondyloarthritis

    Dear Editor,
    I am writing to draw your attention to the profound implications of the article by Baraliakos et al. (1). This study is a beacon of hope for individuals living with axial spondyloarthritis (axSpA) and underscores the potential of Bimekizumab (BKZ) as a transformative treatment.
    The study's findings reveal that BKZ, a monoclonal antibody inhibiting interleukin (IL)-17A and IL-17F, has exhibited unparalleled efficacy in patients with both non-radiographic (nr-) and radiographic (r-) axSpA. These results are not just promising; they are monumental. The study demonstrates that improvements achieved with BKZ at Week 16 persist to Week 52. Key metrics, including Assessment of SpondyloArthritis International Society ≥40% response, Ankylosing Spondylitis Disease Activity Score, high-sensitivity C-reactive protein levels, and MRI inflammation of the sacroiliac joints/spine, continued to improve in patients who received BKZ.
    Of equal significance is the fact that patients who transitioned from a placebo to BKZ at Week 16 experienced comparable results to those who received BKZ from the outset. This underlines the sustained efficacy of BKZ and its potential to improve the quality of life for axSpA patients. Furthermore, BKZ demonstrated the ability to reduce objective measures of inflammation, such as MRI scores and hs-CRP levels, consistently across treatment groups. These reductions correlate with improvements in patient-reported outcomes, includ...

    Show More
    Conflict of Interest:
    None declared.